Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPPTH trial of papaverine during total thyroidectomy
2026-527270-37-00Phase 2Authorised
- Sponsor
- Azienda Provinciale per i Servizi Sanitari
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of papaverine in hypoparathyroidism (2 arms), sponsored by Azienda Provinciale per i Servizi Sanitari. Primary endpoint: Primary endpoint: biochemical postoperative hypoparathyroidism on postoperative day 1. Planned start Nov 2026; status: authorised.
02
Drugs
papaverine
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on 2026-527270-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527270-37-00.